Navigation Links
Experimental vaccine protects lab animals against several strains of H5N1

Nations are preparing to stockpile vaccines against H5N1, the strain of influenza virus that experts fear could cause the next flu pandemic. But will these vaccines remain effective as the virus mutates? Researchers present good news in the July 15 issue of The Journal of Infectious Diseases, now available online.

Elena Govorkova, MD, PhD, Robert G. Webster, PhD, and coworkers at St. Jude Children's Research Hospital in Memphis, Tenn., used reverse genetics to develop an influenza virus with two key proteins on its surface derived from an H5N1 strain. They inactivated the virus and used it to vaccinate ferrets. The vaccine protected the ferrets from getting sick when exposed not only to the flu strain from which the vaccine was made, but also two other strains, including a deadly strain labeled A/Vietnam/1203/04.

Cross-strain protection is exactly what one would need, as it would protect against newly emerging variants until a strain-specific vaccine can be developed. The reverse genetics method used by the St. Jude investigators would allow rapid vaccine preparation, which is crucial in a potentially fast-moving pandemic. Other undertaken vaccine approaches have serious shortcomings. Wild-type H5N1 vaccines, for example, cannot be produced on a large scale because of their marked virulence, and vaccines based on less-virulent H5N1 strains have so far been relatively poor stimulators of immunity in human trials.

In the study, the ferrets were vaccinated intramuscularly with one or two doses of vaccine. Both schedules induced a protective antibody response, but the two-dose schedule induced higher levels of antibodies that were cross-reactive to various H5N1 viruses. Human clinical trials have seen similar results, suggesting that two doses of vaccine will be required to effectively protect against an H5N1 flu strain.

In an accompanying editorial, Alan W. Hampson, MSc, of the Australian Influenza Specialist Group, noted that the succe ssful use of a genetically modified whole-virus vaccine that produced protective antibodies against H5N1 virus in ferrets suggests that the ferret model has the potential to provide useful information in assessing vaccines when human data alone are inadequate.

"Possibly the greatest significance of the current study, he added, "is the demonstration of a significant cross-strain protective effect," a finding that "strengthens the argument for stockpiling vaccines prepared from currently available H5N1 vaccine strains."


'"/>

Source:Infectious Diseases Society of America


Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
5. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
6. Experimental RNA-based drug kills prostate cancer cells effectively and safely
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Research advances quest for HIV-1 vaccine
11. A much-needed shot in the arm for HIV vaccine development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):
(Date:8/11/2017)... ... 11, 2017 , ... “There is an increasing consumer call ... synthetic ingredients,” said Matt Hundt, President of Third Wave Bioactives. “Combining the strong ... know-how of Biorigin will allow us to bring truly novel fermented ingredient technologies ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized ... medium for clinical studies. , Dr. Travis Antes, head of analytical development ...
(Date:8/10/2017)... USA (PRWEB) , ... August 09, 2017 , ... ... partnered with four international biomedical optics laboratories — the Wellman Center for Photomedicine, ... Medical Laser Center Lübeck and the Beckman Laser Institute at University of California, ...
(Date:8/10/2017)... ... August 10, 2017 , ... CNA Finance Chief Research Analyst, ... on Next Group Holdings, Inc. and see's significant opportunity in the company's plans ... cannot engage in traditional banking services. According to industry estimates, approximately 103 million ...
Breaking Biology Technology: